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             Systemic lupus erythematosus (SLE) is a proto-
typic autoimmune disease of largely unknown 
etiology. Genetic and environmental factors such 
as smoking, UV exposure, and infections in-
crease the risk of disease manifestation. Virtually 
every organ in the human body can be involved, 
especially skin, joints, hematopoietic system, kid-
neys, central nervous system, and heart, thereby 
causing an ample variety of symptoms. 
  Autoantibodies against double-stranded DNA 
(dsDNA) and nucleosomes represent a serolog-
ical hallmark of SLE (  1  ). These autoantibodies 
can form immune complexes and immune 
deposits within kidneys and blood vessels and, 
hence, crucially contribute to the pathogen-
esis of lupus nephritis and vasculitis (  2  –  4  ). How-
ever, the mechanisms that cause breakage of 
the immunological tolerance against native 
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  Autoantibodies against double-stranded DNA (dsDNA) and nucleosomes represent a hall-
mark of systemic lupus erythematosus (SLE). However, the mechanisms involved in breaking 
the immunological tolerance against these poorly immunogenic nuclear components are not 
fully understood. Impaired phagocytosis of apoptotic cells with consecutive release of 
nuclear antigens may contribute to the immune pathogenesis. The architectural chromo-
somal protein and proinfl  ammatory mediator high mobility group box protein 1 (HMGB1) is 
tightly attached to the chromatin of apoptotic cells. We demonstrate that HMGB1 remains 
bound to nucleosomes released from late apoptotic cells in vitro. HMGB1  –  nucleosome 
complexes were also detected in plasma from SLE patients. HMGB1-containing nucleo-
somes from apoptotic cells induced secretion of interleukin (IL) 1    , IL-6, IL-10, and tumor 
necrosis factor (TNF)      and expression of costimulatory molecules in macrophages and 
dendritic cells (DC), respectively. Neither HMGB1-free nucleosomes from viable cells nor 
nucleosomes from apoptotic cells lacking HMGB1 induced cytokine production or DC 
activation. HMGB1-containing nucleosomes from apoptotic cells induced anti-dsDNA and 
antihistone IgG responses in a Toll-like receptor (TLR) 2  –  dependent manner, whereas 
nucleosomes from living cells did not. In conclusion, HMGB1  –  nucleosome complexes acti-
vate antigen presenting cells and, thereby, may crucially contribute to the pathogenesis of 
SLE via breaking the immunological tolerance against nucleosomes/dsDNA. 
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    RESULTS   
  Nucleosomes released from late apoptotic cells 
contain HMGB1 
  During apoptotic cell death, oligo- and mononucleosomes are 
generated by internucleosomal cleavage of chromatin by en-
donucleases (  23, 24  ). In vivo, the appearance of nucleosomes 
in the circulation is normally prevented by the eff  ective elim-
ination of apoptotic cells by phagocytes (  25  –  27  ). In vitro, 
nucleosomes are released into culture supernatants when the 
dying cells enter late stages of apoptosis, i.e., secondary ne-
crosis (  28  ). To investigate whether nucleosomes spontane-
ously released from secondary necrotic cells contain HMGB1, 
we induced apoptosis in Jurkat cells either by UV irradiation 
(unpublished data) or staurosporine treatment for 48 h, when 
virtually all cells had undergone secondary necrosis. Primary 
necrosis was induced by heat treatment. Using diff  erent anti-
histone and anti-dsDNA antibodies, HMGB1 was precipitated 
from supernatants of secondary necrotic cells but not from 
those of primary necrotic cells (  Fig. 1  ).   From supernatants of 
primary heat-induced necrotic cells, HMGB1 was precipi-
tated only by anti-HMGB1 antibodies, indicating that HMGB1 
released from primary necrotic cells is not associated with 
nucleosomes. Early apoptotic cells did not release detectable 
amounts of HMGB1 (unpublished data). Hence, nucleosomes 
released from cultured cells undergoing secondary necrosis 
are, at least partially, associated with HMGB1. 
  Circulating nucleosomes in the blood of patients with SLE 
contain HMGB1 
  We and others have previously described that HMGB1 is fre-
quently detectable in plasma and serum of patients with SLE 
(  22, 29  ). Within the peripheral blood of some patients with 
chromosomal DNA and nucleosomes, which by themselves 
are poorly immunogenic, are not understood. 
  High mobility group box protein 1 (HMGB1) is an evo-
lutionary conserved ubiquitously expressed chromosomal 
protein consisting of two positively charged DNA binding 
domains, called HMG box A and B, and a negatively charged 
C-terminal domain (  5  ). HMGB1 binds to dsDNA, single-
stranded DNA (ssDNA), distorted DNA, and nucleosomes. 
HMGB1 stabilizes the structure of nucleosomes and induces 
DNA bending, thereby participating in transcriptional regu-
lation (  6  ). Recently, it has been described that HMGB1 can 
also act as a proinfl  ammatory mediator when released from 
cells. Binding of HMGB1 to the receptor for advanced glyca-
tion end products (RAGE) and Toll-like receptor (TLR) 
2 and TLR4 leads to the recruitment of infl  ammatory cells and 
the release of proinfl  ammatory cytokines including TNF-    , 
IL-1    , and IL-6 (  7  –  11  ). In addition, HMGB1 induces up-regu-
lation of activation markers (HLA-DR, CD83, CD80, and 
CD86) on DC (  12, 13  ). 
  Extracellular HMGB1 may contribute to the pathogene-
sis of several diseases. Wang et al. (  9  ) showed that HMGB1 is 
a crucial mediator of late lethality from septic shock. Extra-
cellular HMGB1 has been reported in experimental arthritis 
models as well as in human rheumatoid arthritis (  14  –  16  ). Im-
portantly, systemic application of either the antagonistic box 
A or HMGB1-neutralizing antibodies ameliorated collagen-
induced arthritis in rodents (  14, 15  ). 
  During apoptosis, a substantial amount of nuclear HMGB1 
gets tightly attached to hypoacetylated chromatin, thereby 
preventing HMGB1 release (  17  ). We hypothesized that in 
case of clearance defi  ciency, as found in 30  –  50% of patients 
with SLE, uningested apoptotic cells may undergo secondary 
necrosis (  18, 19  ). During secondary necrosis, the majority of 
HMGB1 remains bound to nucleosomes in the insoluble 
nuclear remnants (  17  ); however, a fraction of the nucleosomes 
themselves are released in soluble form and may carry along 
the tightly bound proinfl  ammatory HMGB1. 
  It was previously shown that extracellular HMGB1 is 
present within lesional skin in patients with chronic cutane-
ous lupus (  20, 21  ). Moreover, we recently detected HMGB1 
in serum and plasma of patients with SLE (  22  ). In this paper, 
we demonstrate that HMGB1  –  nucleosome complexes are 
released from secondary necrotic cells and can be found in 
the blood of patients with SLE. HMGB1  –  nucleosome com-
plexes purifi  ed from apoptotic cells induced cytokine expres-
sion in macrophages and maturation of DC. In contrast, 
neither nucleosomes from viable cells nor nucleosomes from 
apoptotic cells devoid of HMGB1 and with a low level of 
HMGB2 (HMGB  low  ) induced any marked cytokine release. 
Importantly, immunization with nucleosomes from apoptotic, 
but not with those from viable cells, resulted in signifi  cantly 
increased anti-dsDNA and antihistone antibody titers in non-
autoimmune mice. Hence, nucleosomes with tightly bound 
HMGB1 may play a crucial role in breaking the immunolog-
ical tolerance against dsDNA, which represents a key auto-
antigen in SLE. 
    Figure 1.         HMGB1 is associated with nucleosomes spontaneously 
released during secondary necrosis.   For induction of secondary necrosis 
(SN), Jurkat cells were treated with 2   μ  M staurosporine for 48 h. Primary 
necrosis was induced by heating cells at 56  °  C for 30 min followed by 
incubation for an additional hour at 37  °  C. Supernatants from apoptotic 
(top) and necrotic (bottom) Jurkat cells were collected and subjected to 
immune precipitations with anti-HMGB1, anti-dsDNA, antihistone H3, 
antihistone H2B, and antihistones H2A/H4 as well as with appropriate 
isotype control antibodies. Immune-precipitated material was then frac-
tionated by SDS-PAGE on 12% polyacrylamide gel. Western blot analysis 
was performed using polyclonal anti-HMGB1 antibodies. WB, Western 
blotting; IP, immunoprecipitation. These experiments have been per-
formed four times with virtually identical results.     JEM VOL. 205, December 22, 2008 
ARTICLE
3009
show that nucleosomes circulating in the blood of SLE pa-
tients are associated with HMGB1. 
  Apoptotic cell-derived nucleosomes induce 
a proinfl  ammatory response 
  To investigate whether HMGB1-containing nucleosomes 
derived from apoptotic cells exhibit proinfl  ammatory activ-
ity, we isolated nucleosomes by sucrose gradient ultracentri-
fugation from viable, from staurosporine-treated apoptotic, 
and from heat-induced necrotic Jurkat cells. Mononucleosomes 
were predominantly found in fraction 4 of all preparations as 
demonstrated by detection of mononucleosomal DNA and 
histones (  Fig. 3  ).   In the case of viable cells, HMGB1 was found 
almost exclusively at the top of the gradient in the fractions 
that did not contain nucleosomes/DNA (  Fig. 3 A  ). In prepa-
rations from necrotic cells, only minute amounts of HMGB1 
were detected in the mononucleosomes containing fractions 
4 and 5 (  Fig. 3 B  ). In cells necrotized by other means, such as 
freeze thaw, most HMGB1 was found at the top of the gradi-
ent, and again only minute amounts of HMGB1 were detected 
in association with mononucleosomes or in the high molecu-
lar mass fractions 6  –  8 (unpublished data). Only preparations 
from apoptotic cells contained substantial amounts of HMGB1 
in nucleosomal fractions 4 and 5 (  Fig. 3 C  ). In addition, rela-
tively large quantities of HMGB1 were found at the top of the 
density gradient from apoptotic cells, indicating free HMGB1. 
Fraction 4, mainly containing mononucleosomes, was ana-
lyzed by SDS-PAGE and Coomassie blue staining of gels to 
SLE, high amounts of circulating immune complexes, which 
often contain nucleosomes, can be detected (  30  –  32  ). To test 
if these circulating immune complexes contain HMGB1, im-
mune complexes were precipitated from sera of patients with 
SLE and other diseases, including rheumatoid arthritis, aller-
gies, and infections, as well as from healthy controls, and ana-
lyzed by Western blotting. In six of eight SLE sera, HMGB1 
was readily detectable. In contrast, in precipitates of 4 healthy 
donors and 10 non-SLE patients, no or very little HMGB1 
could be detected (  Fig. 2 A   and not depicted).   
  To explore whether HMGB1 is associated with circulat-
ing DNA/nucleosomes in the blood of SLE patients, we per-
formed coimmunoprecipitations using antibodies covalently 
coupled to Sepharose beads. With antihistone and anti-ds-
DNA/nucleosome antibodies, we could coprecipitate HMGB1 
from HMGB1-containing sera of SLE patients but not from 
sera of healthy donors (  Fig. 2 B  ). Results similar to those 
shown in   Fig. 2 B   were obtained with additional sera from 
SLE patients (  n   = 6) and healthy controls (  n   = 5). These data 
    Figure 2.         Nucleosomes circulating in the blood of patients with 
SLE are complexed with HMGB1.   (A) Circulating immune complexes in 
the blood of patients with SLE contain HMGB1. Immune complexes from 
serum samples of patients with SLE and rheumatoid arthritis (RA) as well 
as from healthy persons (NHD, normal healthy donors) were precipitated 
by 1.5 or 2% of polyethylene glycol (PEG). The precipitates were dissolved 
in SDS sample buffer and analyzed by Western blotting using polyclonal 
anti-HMGB1 antibodies. (B) Antihistone and anti-dsDNA antibodies co-
immunoprecipitate HMGB1 from sera of patients with SLE. Serum samples 
obtained from patients with SLE and normal healthy donors were sub-
jected to coimmunoprecipitation using antihistone and anti-dsDNA anti-
bodies covalently linked to protein G Sepharose. Sepharose beads alone or 
linked to isotype control antibodies served as negative controls. The pre-
cipitates were separated by reducing SDS-PAGE on a 12.5% polyacryl-
amide gel followed by Western blot analysis using polyclonal anti-HMGB1 
antibodies.   
    Figure 3.         HMGB1 cofractionates with nucleosomes from apoptotic 
cells.   For induction of apoptosis, Jurkat cells were treated with 1   μ  M 
staurosporine for 8 h. Necrosis was induced by heat treatment at 56  °  C for 
30 min. Nuclei isolated from viable (A), necrotic (B), and apoptotic 
(C) Jurkat cells were digested with micrococcal nuclease, lysed, and frac-
tionated by sucrose gradient ultracentrifugation. Eight fractions were 
collected in each gradient from top (  1  ) to bottom (  8  ), and individual frac-
tions were analyzed by 1.5% agarose gel electrophoresis in the presence 
of 1% SDS. HMGB1 was detected by Western blotting. (D) Characteriza-
tion of mononucleosomes. 10   μ  g of total protein of mononucleosomal 
fraction 4 purifi  ed from necrotic (lane 1), viable (lane 2), and apoptotic 
(lane 3) Jurkat cells was subjected to a 15% SDS-PAGE. The proteins were 
visualized by Coomassie blue staining.     3010 HMGB1  –  NUCLEOSOME COMPLEXES IN SLE   | Urbonaviciute et al. 
there was no signifi  cant diff  erence in cytokine induction 
by nucleosomes prepared from early or late apoptotic cells 
(Fig. S1, available at http://www.jem.org/cgi/content/full/
jem.20081165/DC1). Importantly, nucleosomes spontaneously 
released from late apoptotic cells also induced cytokine release 
from human monocyte-derived macrophages (Fig. S2). These 
data indicate that the cytokine-inducing capacity of mono-
nucleosomes correlates with their HMGB1 content. 
  HMGB proteins are required for the proinfl  ammatory 
activity of apoptotic nucleosomes 
  To further test whether HMGB1 contributes to the proin-
flammatory activity of apoptotic nucleosomes, we isolated 
nucleosomes from   Hmgb1        /      (containing HMGB2) mouse 
embryonic fi  broblasts (MEF) (  33  ) and HMGB  low   (defi  cient 
for HMGB1 and expressing only trace amounts of HMGB2) 
MEF from their WT counterparts and compared their cyto-
kine-inducing capacity. Primary human monocyte-derived 
macrophages were incubated with nucleosomes purifi  ed from 
viable and apoptotic MEF, and the secretion of TNF-     and 
IL-10 was assessed. Nucleosomes purified from apoptotic 
  Hmgb1        /      MEF induced only low amounts of TNF-     and 
IL-10 (unpublished data) and those prepared from HMGB  low   
fi  broblasts induced virtually no cytokines, which is compara-
ble to nucleosomes from viable cells. In contrast, nucleo-
somes purifi  ed from dying WT fi  broblasts stimulated TNF-     
and IL-10 secretion (  Fig. 5 A  ).   Therefore, HMGB1 and, pre-
sumably, HMGB2 are required for cytokine secretion induced 
by nucleosomes derived from apoptotic cells. 
  To specifi  cally antagonize the eff  ects of HMGB1, we used 
recombinant box A (the truncated N-terminal domain of 
HMGB1), which acts as a competitive inhibitor of the full-
length HMGB1 protein (  34, 35  ). Human monocyte-derived 
macrophages were incubated with nucleosomes purifi  ed from 
apoptotic Jurkat cells in the presence or in the absence of 
10   μ  g/ml of recombinant A box. Treatment with the recom-
binant A box strongly inhibited the cytokine stimulating ac-
tivity of apoptotic nucleosomes, whereas LPS-induced TNF-     
and IL-10 release were not altered (  Fig. 5 B  ). 
  Apoptotic nucleosome-induced cytokine release 
is dependent on TLR2 but not on TLR4, TLR9, and RAGE 
  Previous studies indicated that HMGB1 is an endogenous 
ligand of RAGE, TLR2, and TLR4, whereas CpG oligonucle-
otide signaling depends on TLR9. The adaptor protein 
MyD88 (myeloid diff  erentiation primary response protein 88) 
is critical for signal transduction leading to proinfl  ammatory 
cytokine gene induction upon activation of all these TLRs 
(  36, 37  ). To evaluate the relevance of RAGE and TLR signal-
ing in mediating the proinfl  ammatory eff  ect of apoptotic nu-
cleosomes, we incubated nucleosomes purifi  ed from viable 
and apoptotic cells with thioglycollate-elicited peritoneal 
macrophages obtained from WT and mice defective for 
RAGE (  38  ), MyD88 (  39  ), TLR9 ( 40  ), TLR2, TLR4 ( 41  ), or 
TLR2/4 signaling. The release of TNF-     and IL-10 upon 
exposure to apoptotic nucleosomes was completely abolished 
proof the predominant composition of histones and the pu-
rity of the preparations (  Fig. 3 D  ). Collectively, these data dem-
onstrate that HMGB1 is primarily attached to nucleosomes 
from apoptotic cells. 
  To compare the capacity for macrophage activation, we 
exposed human monocyte-derived macrophages to 20   μ  g/ml 
of nucleosomes from viable, necrotic, and apoptotic cells. 
After 24 h, concentrations of TNF-    , IFN-    , IFN-    , IL-1    , 
IL-6, IL-8, IL-10, and IL-18 were determined in culture su-
pernatants (  Fig. 4  ).   Apoptotic nucleosomes, which contained 
substantial amounts of HMGB1, potently stimulated the secre-
tion of TNF-    , IL-1    , IL-6, and IL-10, whereas nucleosomes 
from viable cells, which did not contain HMGB1, failed to 
induce cytokine release. Nucleosomes from necrotic cells con-
taining less HMGB1 than those from apoptotic cells induced 
measurable cytokine secretion but less than apoptotic nucleo-
somes (  Fig. 4  ). We could not detect IFN-    , IFN-    , IL-8, and 
IL-18 secretion by human macrophages after exposure to nu-
cleosomes (unpublished data). Similar results were obtained 
using mouse peritoneal macrophages (unpublished data). 
Nucleosomes isolated from cells treated with other inducers 
of apoptosis, such as anti-Fas antibodies or UV irradiation, 
elicited comparable cytokine release to nucleosomes from 
staurosporine-treated cells (unpublished data). Furthermore, 
    Figure 4.         HMGB1-containing nucleosomes from apoptotic cells 
induce secretion of cytokines by human monocyte-derived macro-
phages.   Human macrophages were cultured in the absence or presence 
of 20   μ  g/ml of nucleosomes purifi  ed from viable (NC V), apoptotic (NC A), 
and necrotic cells (NC N) or diluent (PBS). Untreated human macrophages 
served as controls. Cell culture supernatants were harvested after 24 h 
and cytokine concentrations were determined. One representative of three 
independent experiments is shown. Mean values and SD were calculated 
from triplicates. Student  ’  s   t   test was used for statistical analysis. **, P   ≤   
0.01; *, P   ≤   0.05.     JEM VOL. 205, December 22, 2008 
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CD80 and B7-2/CD86 (  44  ). To determine whether nucleo-
somes, particularly those derived from apoptotic cells, can in-
duce DC maturation, monocyte-derived immature DC were 
cultured in the absence or presence of 20   μ  g/ml of nucleo-
somes purifi  ed from viable and apoptotic Jurkat cells. After 
48 h, the expression of MHC class II, CD86, and CD83 mole-
cules on the surface of DC was assessed by fl  ow cytometry. 
Only the HMGB1-containing nucleosomes from apoptotic 
cells signifi  cantly induced surface expression of MHC class II, 
the costimulatory molecule CD86, and the DC maturation 
marker CD83 (  Fig. 7 A  ).   In addition to maturation, apoptotic 
nucleosomes also induced TNF-     release from monocyte-
derived DC (unpublished data). 
in MyD88-defi  cient macrophages as well as in TLR2/4- and 
TLR2-defi  cient macrophages. In contrast, cytokine secretion 
from RAGE-defi  cient, TLR4 mutant, and TLR9-defi  cient 
macrophages was not impaired (  Fig. 6  ).   Therefore, TLR2 is 
critical for proinfl  ammatory signaling induced by HMGB1 
containing nucleosomes, whereas RAGE, TLR4, and TLR9 
are dispensable. 
  Nucleosomes induce maturation of DC 
  DC, as the most potent APC, may be critically involved in the 
pathogenesis of SLE by activating naive autoreactive T helper 
lymphocytes (  42, 43  ). Effi   cient T cell priming requires mature 
DC expressing MHC class II together with costimulatory 
molecules such as members of the B7 family, namely B7-1/
    Figure 5.         HMGB1 contributes to the proinfl  ammatory activity of 
apoptotic cell  –  derived nucleosomes.   (A) Nucleosomes isolated from 
apoptotic WT, but not from HMGB  low   MEF, stimulated human monocyte-
derived macrophages to release TNF-     and IL-10. Macrophages were 
incubated with 20   μ  g/ml of nucleosomes purifi  ed from viable (NC V) and 
apoptotic (NC A) WT or HMGB  low   MEF. Untreated macrophages served as 
control. After 24 h, concentrations of TNF-     and IL-10 were measured by 
ELISA. (B) Apoptotic nucleosome-induced cytokine release was suppressed 
by the antagonistic A box domain of HMGB1. Macrophages were stimu-
lated either with 20   μ  g/ml of nucleosomes purifi  ed from apoptotic cells or 
100 ng/ml LPS in the absence or presence of 10   μ  g/ml of the recombinant 
A box fragment. After incubation for 24 h, cell culture supernatants were 
harvested and concentrations of the cytokines TNF-     and IL-10 were 
measured by ELISA. Untreated macrophages served as a control. One rep-
resentative example of three experiments is shown. Mean values and SD 
were calculated from triplicates. Student  ’  s   t   test was used for statistical 
analysis. **, P   ≤   0.01; *, P   ≤   0.05.     
    Figure 6.         Apoptotic nucleosome  –  induced cytokine release by mac-
rophages is dependent on MyD88 and TLR2 but not on TLR4, TLR9, 
and RAGE.   Thioglycollate-elicited peritoneal macrophages were obtained 
from WT, MyD88-, TLR9-, TLR2/4-, TLR2-, and RAGE-defi  cient or TLR4 
mutant mice and incubated with 20   μ  g/ml of nucleosomes purifi  ed from 
viable (NC V) and apoptotic (NC A) Jurkat cells for 24 h. Untreated macro-
phages served as a control. Concentrations of TNF-     and IL-10 were mea-
sured by ELISA. Mean values and SD were calculated from triplicates. 
Student ’ s   t   test was used for statistical analysis. ***, P   ≤   0.001; **, P   ≤   0.01; 
*,  P   ≤   0.05.   3012 HMGB1  –  NUCLEOSOME COMPLEXES IN SLE   | Urbonaviciute et al. 
  To investigate if apoptotic nucleosome-induced maturation 
of DC is also relevant for DC function, we cocultured mono-
cyte-derived DC in the absence or in the presence of nucleo-
somes isolated from either viable or apoptotic cells. After 48 h, 
allogeneic T cells were added and their proliferative response 
was assessed. The mixed leukocyte reaction was signifi  cantly 
enhanced by DC preincubated with nucleosomes from apop-
totic cells but not by DC preincubated with nucleosomes from 
viable cells (  Fig. 7 B  ). These data indicate that the capacity of 
DC to activate T cells is increased by apoptotic nucleosomes. 
  To further test if HMGB1 is involved in DC maturation 
induced by nucleosomes from apoptotic cells, immature DC 
were exposed to nucleosomes isolated from either WT or 
HMGB  low   MEF for 48 h. Expression of CD83 and CD86 on 
the surface of DC was assessed by fl  ow cytometry. Nucleo-
somes isolated from apoptotic WT MEF signifi  cantly up-
regulated expression of CD83 and CD86 on DC, whereas 
nucleosomes from HMGB  low   MEF displayed only a subtle 
eff  ect on the surface expression of CD83 and CD86 (  Fig. 7 C  ). 
These data demonstrate that HMGB1-containing nucleosomes 
from apoptotic cells can induce maturation of DC, which is 
essential for effi   cient antigen presentation. 
  IFN-     released from plasmacytoid DC (pDC) may criti-
cally contribute to the immunopathogenesis of SLE and can 
be induced by CpG oligonucleotides and, even more effi   ciently, 
by HMGB1 CpG oligonucleotide complexes in a TLR9- 
and RAGE-dependent manner (  10, 11  ). In our experiments, 
neither nucleosomes from viable nor from apoptotic cells 
induced expression of IFN-     or maturation markers in pDC 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20081165/DC1; and not depicted). However, if pDC 
were incubated with nucleosomes in addition to anti-dsDNA 
containing SLE serum, there was a strong induction of IFN-     
release (Fig. S3). These date indicate that IFN-     secretion 
from pDC does not depend on HMGB1 attached to nucleo-
somes but on immune complex formation. 
  Increased immunogenicity of nucleosomes 
from apoptotic cells 
  To test whether HMGB1-containing nucleosomes from apop-
totic cells display increased immunogenicity in vivo, we im-
munized BALB/c mice with nucleosomes isolated from viable 
and apoptotic Jurkat cells. Adult female mice were injected 
three times i.v. with nucleosomes without any adjuvant. Con-
trols were injected with PBS. The concentrations of anti-ds-
DNA, anti-ssDNA, and antihistone antibodies were measured 
by ELISA. 
    Figure 7.         Nucleosomes induce maturation of DC.   (A)  Monocyte-
derived DC were cultured in the absence or presence of 20   μ  g/ml of nu-
cleosomes purifi  ed from viable (NC V) or apoptotic (NC A) Jurkat cells. 
After incubation for 48 h, expression of MHC class II, CD86, and CD83 
molecules was assessed by fl  ow cytometry. The results are expressed as 
mean fl  uorescence intensity (MFI). On the left, bar graphs show means 
and SD of triplicates. On the right, corresponding representative histo-
grams are shown. Gray line, unstimulated DC; black line, DC exposed to 
nucleosomes from viable cells; fi  lled gray, DC exposed to nucleosomes 
from apoptotic cells. (B) DC exposed to nucleosomes from apoptotic cells 
are more potent stimulators of allogeneic T cells than DC exposed to nu-
cleosomes from viable cells. Immature DC were incubated for 48 h with 
nucleosomes purifi  ed from viable or apoptotic cells or LPS as positive 
control. DC were then cocultured with allogeneic T cells at a DC/T cell 
ratio of 1:100. T cell proliferation was assessed by measuring the amount 
of   3  H thymidine incorporation. Mean values and SD were calculated from 
triplicates.  Student ’ s   t   test was used for statistical analysis. **, P   ≤   0.01. 
(C) HMGB1 contributes to the apoptotic nucleosome  –  induced DC activa-
tion. Human monocyte-derived DC were left untreated or incubated with 
20   μ  g/ml of nucleosomes purifi  ed from viable or apoptotic WT or HMG-
B  low   MEF. After 48 h, expression of CD83 and CD86 on the surface of DC 
was determined by fl  ow cytometry. The results are expressed as mean 
fl  uorescence intensity. Student  ’  s   t   test was used for statistical analysis. 
**, P   ≤   0.01; *, P   ≤   0.05. Experiments were repeated three times using DC 
generated from different donors.     
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mice produced also antibodies to Jo-1, Sm, SSA/Ro, and 
SSB/La. Furthermore, most mice injected with apoptotic nu-
cleosomes showed a trend toward increased concentrations 
of antibodies to U1-RNP, SSA/Ro, and SSB/La. Antibodies 
to the lupus-specifi  c Sm antigen were signifi  cantly increased 
in mice immunized with nucleosomes from apoptotic cells 
compared with those immunized with nucleosomes from viable 
cells (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20081165/DC1; and not depicted). Nucleosomes 
from apoptotic MEF also induced anti-dsDNA antibodies in 
BALB/c mice (unpublished data). 
  To evaluate the requirement of TLR2 for the immuno-
genicity of apoptotic cell  –  derived nucleosomes in vivo, TLR2- 
and TLR2/4-defi  cient mice, as well as C57BL/6 WT mice, 
were injected i.v. three times with mononucleosomes prepared 
from apoptotic cells. TLR2- and TLR2/4-defi  cient mice de-
veloped very low concentrations of anti-dsDNA and antihis-
tone antibodies, which were markedly lower than in C57BL/6 
WT controls (  Fig. 8 B  ). 
  These in vivo experiments demonstrate that nucleosomes 
derived from apoptotic cells more effi   ciently induce antibodies 
to dsDNA, histones, and various extractable nuclear antigens 
compared with those from viable cells. Moreover, the engage-
ment of TLR2 is critical for the induction of anti-dsDNA and 
histone IgG autoantibodies in mice. 
    DISCUSSION   
  Nucleosomes appear to be a crucial primary autoantigen in SLE, 
and autoantibodies against dsDNA and nucleosomes are a 
characteristic feature of SLE (  30, 45, 46  ). Usually, purifi  ed 
dsDNA and nucleosomes are poorly immunogenic (  47, 48  ). 
It is still unknown why nucleosomes, which are ubiquitous 
and abundant self components, become immunogenic in SLE. 
Mono- and oligonucleosomes are formed during apoptosis by 
cleavage of chromatin and might appear on the cell surface 
and in apoptotic blebs at later stages of the apoptotic death 
process (  23, 24, 49  ). Normally, apoptotic cells are removed 
swiftly by phagocytes before nucleosomes are released. How-
ever, if dying cells enter late stages of apoptosis, nucleosomes 
are released (  28  ). We detected nucleosomes complexed with 
HMGB1 in the supernatants of secondary necrotic but not 
primary necrotic cells. Hence, in conditions with impaired 
clearance of apoptotic cells, as is observed in a subset of pa-
tients with SLE (  18, 19  ), nucleosomes complexed with the 
endogenous adjuvant HMGB1 may get released and foster an 
autoimmune response. 
  In fact, nucleosomes are often detectable in the blood of 
patients with SLE and are thought to result from in vivo cell 
death (  30, 50  ). Nucleosomes and DNA appeared in a dose-
dependent manner in the plasma of mice treated with apop-
tosis-inducing agents (  51  ). In SLE, nucleosomes predominantly 
exist in the form of immune complexes because of the presence 
of respective autoantibodies (  52  ). We detected HMGB1 in cir-
culating immune complexes from SLE patients but not from 
controls. Because of the presence of autoantibodies to HMGB1 
in a substantial number of patients with SLE (  22, 53  ), there 
  Mice injected with apoptotic cell  –  derived nucleosomes 
displayed a signifi  cant increase in serum IgG antibodies directed 
to dsDNA and histones compared with mice immunized with 
nucleosomes from viable cells, which showed only slight or no 
anti-dsDNA and antihistone responses. None of the groups dis-
played a relevant increase in anti-ssDNA IgG titers (  Fig. 8 A  ).   
In addition, sera were tested for extractable nuclear antigens. 
Mice immunized with nucleosomes from viable cells showed 
no relevant increase in these autoantibodies, whereas two of 
the mice immunized with nucleosomes from apoptotic cells 
displayed high titers of anti-Scl70 antibodies. One of these 
    Figure 8.         Increased immunogenicity of nucleosomes derived from 
apoptotic cells and involvement of TLR2 in the autoimmune re-
sponse.   (A) Groups of fi  ve BALB/c mice each were i.v. immunized three 
times with 50   μ  g of purifi  ed nucleosomes from viable and apoptotic Jur-
kat cells in intervals of 3 wk. A control group received PBS. Sera were 
collected before the fi  rst immunization and 3 wk after each immuniza-
tion. Concentrations of IgG antibodies against nucleosomes, ssDNA, ds-
DNA, and histones were determined by ELISA. All sera were tested in the 
same assay. Mean values of the OD and SD are shown. Statistical analysis 
was performed using the nonparametric Mann-Whitney   U   test for un-
paired samples. **, P   ≤   0.01; *, P   ≤   0.05. (B) To evaluate the requirement of 
TLR2 for the production of autoantibodies in vivo, groups of TLR2     /   , 
TLR2/4     /    , and C57BL/6 mice were i.v. injected with 75   μ  g of purifi  ed 
nucleosomes from apoptotic cells in intervals of 2 wk. 2 wk after the third 
immunization, anti-dsDNA and antihistone IgG antibodies were quanti-
fi  ed in serum samples by ELISA. All sera were tested in the same assay. 
Bars indicate the mean values. Statistical analyses were performed using 
the Student  ’  s   t   test for unpaired samples. *, P   ≤   0.05.     3014 HMGB1  –  NUCLEOSOME COMPLEXES IN SLE   | Urbonaviciute et al. 
binds more effi   ciently to RAGE than HMGB1 alone. The CpG 
oligonucleotide-mediated TLR9-dependent cytokine release 
from B cells and pDC was strongly enhanced by HMGB1 and 
was dependent on RAGE and TLR9. However, the exact 
mechanism remained unclear (  10  ). 
  In contrast to these data on HMGB1  –  CpG oligonucleotide 
complexes, HMGB1-containing nucleosomes from apoptotic 
cells induced cytokine release from macrophages indepen-
dently of RAGE, TLR4, and TLR9, whereas only TLR2 
signaling was essential. The immunization of TLR2-defi  cient 
mice with apoptotic nucleosomes did not result in a marked 
induction of anti-dsDNA or antihistone antibodies, a fact which 
confi  rmed the crucial role of TLR2 for the immune stimula-
tory eff  ect of HMGB1  –  nucleosome complexes in vivo. In-
terestingly, the presence of a single loss-of-function allele of 
the Mal/TIRAP protein, which is essential for TLR2- and 
TLR4-mediated signal transduction, was found to be protective 
against SLE, whereas it had no infl  uence on the occurrence 
of rheumatoid arthritis (  61  ). Based on our results, HMGB1 
might represent the link between TLR2 signaling and the 
pathogenesis of SLE. As it has been shown in MRL/lpr mice 
(  62  ), the formation of autoantibodies to dsDNA and ribonu-
cleoprotein particles may additionally require TLR9 and 
TLR7, respectively. 
  In contrast to CpG oligonucleotides and CpG  –  HMGB1 
complexes, HMGB1  –  nucleosome complexes by themselves 
did not cause IFN-     release from pDC. However, in the pres-
ence of sera containing high concentrations of anti-dsDNA 
antibodies together with nucleosomes, there was a strong 
induction of IFN-    , which may play a crucial role in the 
immunopathogenesis of SLE (Fig. S3) (  63  ). Moreover, prelimi-
nary data indicate that in mice immunized with nucleosomes 
from apoptotic cells, but not from viable cells, subsequent in-
jections of nucleosomes induced IFN-     release in vivo. These 
data suggest that apoptotic nucleosomes may initiate autoan-
tibody formation to dsDNA. Subsequent release of nucleosomes 
leads to the formation of immune complexes and IFN-     se-
cretion, which then acts as an amplifi  cation loop of autoim-
munity and infl  ammation (Fig. S5). 
  DC are important regulators of immune responses. Mature 
DC are especially required for the priming of T helper cells. 
DC mature upon recognition of pathogens (  64  ). DC-medi-
ated autoimmune responses can occur also in the absence of 
pathogens. Under such conditions, endogenous molecules act-
ing as alarmins may activate APC and enhance the expression 
of costimulatory and MHC class II molecules (  65  ). It has 
been previously demonstrated that recombinant HMGB1 and 
the HMGB1 B box (  12  ) as well as HMGB1-containing super-
natants from WT MEF, but not from their   Hmgb1        /      coun-
terparts, induced maturation of DC (  13  ). In addition, other 
groups demonstrated that chromatin/nucleosome-containing 
immune complexes (  66  ) and free nucleosomes purifi  ed from 
calf thymus directly interact with DC and can activate them 
via TLR9-dependent and -independent pathways (  46  ). In this 
paper, we demonstrated that apoptotic cell  –  derived nucleo-
somes induced markedly stronger DC maturation as compared 
could also be immune complexes containing only HMGB1. 
However, coimmunoprecipitation experiments revealed that 
HMGB1 that was detectable in the serum and plasma of SLE 
patients was, at least partially, associated with dsDNA and nu-
cleosomes. No HMGB1-containing immune complexes were 
detectable in healthy individuals, although anti-HMGB1 an-
tibodies were also present (  22, 53  ). Most likely, in healthy 
subjects HMGB1 is usually not released because of a rapid 
clearance of dying cells; hence, no immune complexes are 
formed. Previous studies demonstrated that, in apoptotic cells, 
HMGB1 is fi  rmly bound to hypoacetylated chromatin, even 
after undergoing secondary necrosis. In contrast, HMGB1 is 
rapidly lost from chromatin of primary necrotic cells (  17  ). 
Therefore, HMGB1  –  nucleosome complexes in the blood of 
patients with SLE might be predominantly derived from sec-
ondary necrotic rather than from primary necrotic cells. 
  Recent findings of Bell et al. (  54  ) demonstrated that 
HMGB1 release may not be an exclusive feature of primary 
necrosis. At least in certain cells, HMGB1 release occurs also 
during late apoptotic cell death, even before release of DNA 
(  54  ). In this paper, we show that at least some of the HMGB1, 
which is released from secondary necrotic cells, is bound to 
nucleosomes. Nucleosomes from viable cells contained virtu-
ally no HMGB1. Only a fraction of apoptotic cell  –  derived 
nucleosomes contained HMGB1, suggesting that the formation 
of high-affi   nity complexes between nucleosomes and HMGB1 
is restricted to certain subsets of nucleosomes and/or HMGB1. 
The amount of these complexes may depend on cell types 
and diff  erent apoptotic pathways. 
  Most importantly, apoptotic cell  –  derived nucleosomes 
displayed a potent proinfl  ammatory eff  ect. Nucleosomes pu-
rifi  ed from HMGB1-defi  cient apoptotic MEF induced very 
little TNF-     and IL-10 secretion. Those from HMGB  low   cells, 
which are defi  cient for HMGB1 and very low in HMGB2, 
did not stimulate any TNF-     or IL-10 release. These data in-
dicate a direct and critical role of HMGB1 in the proinfl  am-
matory properties of nucleosomes derived from apoptotic 
cells and suggest that HMGB2, which displays a similar amino 
acid sequence and shares many if not all of the biochemical 
properties with HMGB1 (  5, 55  ), also exhibits a proinfl  amma-
tory potential. Notably, TNF-    , IL-6, and IL-10, which are 
induced by apoptotic nucleosomes, are elevated in the serum 
of patients with SLE and may contribute to the pathogenesis 
of SLE (  56, 57  ). However, the role of TNF-     appears to be 
ambivalent in SLE. On one side, IFN-    /     production, which 
may contribute to the immune pathogenesis of SLE, is nor-
mally down-regulated by TNF-     (  58  ). On the other side, 
TNF-     is found in the serum and infl  amed kidneys of SLE 
patients and might contribute to the infl  ammatory process 
and organ damage (  59  ). In SLE, TNF-     may fail to regulate 
IFN-     production adequately (  56  ), and a combined increase 
of both cytokines could promote the pathogenesis. 
  Most of the biological eff  ects of HMGB1 are proposed to 
be mediated by the multiligand receptor RAGE as well as 
TLR2 and 4 (  8, 10, 11, 15, 60  ). A very recent study demon-
strated that HMGB1, in complex with CpG oligonucleotides, JEM VOL. 205, December 22, 2008 
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were provided by B. Arnold (German Cancer Research Center, Heidelberg, 
Germany) (  38  ), TLR9      /      mice by T. Winkler (Department of Biology, 
University of Erlangen-N  ü  rnberg, Erlangen, Germany) (  40  ), TLR2      /     , 
TLR4      /      (  41  ), and TLR2/4      /      mice by M. Schnare (Institute of Medical 
Microbiology and Immunology, University of Erlangen-N  ü  rnberg, Erlan-
gen, Germany), and MyD88      /      (  39  ), TLR4 mutant (C3H/HeJ), and corre-
sponding WT control (C3H/HeN) mice by A. Gessner and J. Glaesner 
(Institute of Medical Microbiology and Immunology, University of Erlan-
gen-N  ü  rnberg, Erlangen, Germany). 
  Induction of apoptosis and necrosis.     For induction of apoptosis, Jurkat 
cells (2.5   ×   10  6   cells/ml) were treated with 1   μ  M staurosporine (Enzo Bio-
chem, Inc.) for 4  –  8 h for preparation of nucleosomes and for 48 h for co-
immunoprecipitations. For preparation of nucleosomes, HMGB  low   and WT 
MEF were treated with 0.5   μ  M staurosporine for 4  –  8 h. Primary necrosis 
was induced by heating cells at 56  °  C for 30 min followed by incubation for 
an additional hour at 37  °  C. Apoptotic and necrotic cell death were con-
fi  rmed by staining with propidium iodide/annexin V-FITC. 
  PEG precipitation of immune complexes.     Circulating immune com-
plexes from serum samples were precipitated with either 1.5 or 2% PEG 
6000 (Carl Roth). The precipitates were separated in a 12% SDS polyacryl-
amide gel, and HMGB1 was detected by Western blotting using polyclonal 
anti-HMGB1 antibodies (BD). 
  Preparation of nucleosomes.     Nucleosomes were prepared from Jurkat 
cells (5   ×   10  8   cells per preparation) and HMGB WT and HMGB  low   MEF 
(2   ×   10  8   cells per preparation) after staurosporine treatment for 4  –  8 h. Nuclei 
were isolated according to Vaux et al. (  71  ). Chromatin fractions containing 
mononucleosomes were obtained based on the method described by Suer 
et al. (  72  ). In brief, isolated nuclei were digested with 500 U of micrococcal 
nuclease (S7; Roche) for 30 min at 37  °  C, lysed with 10 mM Tris and 2 mM 
EDTA, and the suspension was layered onto 12 ml of a 10  –  50% sucrose gra-
dient. The gradients were centrifuged at 34,000 rpm for 22 h at 4  °  C in a 
SW41 Beckman rotor. Fractions of 1.5 ml were collected and analyzed for 
DNA content by 1.5% agarose gel electrophoresis in the presence of 0.1% 
SDS followed by visualization with ethidium bromide. Histones and 
HMGB1 were detected by 15% SDS PAGE and Coomassie staining as well 
as Western blotting. Before use, the nucleosome fractions were extensively 
dialysed against PBS. To exclude contaminations with LPS, we used sterile 
endotoxin-free plastic ware and reagents for nucleosome preparations. All 
nucleosome preparations were tested for LPS contaminations using the 
E-TOXATE kit (Sigma-Aldrich) and the QCL-1000 chromogenic endo-
toxin detection assay (Cambrex). Nucleosome preparations were used only 
if the Limulus (E-TOXATE) assay was negative and the endotoxin concen-
tration was   <  0.2 U/ml as detected by QCL-1000. 
  Western blot analyses.     Equal amounts of each fraction obtained by su-
crose gradient ultracentrifugation were subjected to 12% SDS-PAGE and 
transferred onto a PVDF membrane (Millipore). Proteins were visualized as 
described previously (  22  ). 
  Coimmunoprecipitation.     Coimmunoprecipitations were performed 
using the Seize X Mammalian Immunoprecipitation kit (Thermo Fisher 
Scientifi  c) according to the manufacturer  ’  s instructions with minor modifi  -
cations. In brief, 7.5   μ  g of anti-HMGB1 (R  &  D Systems), anti-dsDNA 
(33H11; provided by T. Winkler, University of Erlangen-N  ü  rnberg, Er-
langen, Germany), antihistone pan (Roche), antihistone KM1 and KM2 
(provided by J. Berden, Nijmegen Medical Center, Nijmegen, Nether-
lands), and antihistone H3 (Abcam) antibodies and 7.5   μ  g/ml of appropriate 
isotype control antibodies were covalently coupled to protein G  –  Sepharose 
beads and incubated either with serum samples or cell culture supernatants 
of apoptotic or necrotic Jurkat cells at 4  °  C for 4 h. Precipitated proteins 
were analyzed by Western blotting with polyclonal anti-HMGB1 antibod-
ies (Millipore). 
with those from viable cells. In addition, nucleosomes de-
rived from apoptotic HMGB  low   MEF did not induce DC mat-
uration, again demonstrating a critical role of HMGB proteins 
acting as endogenous adjuvants enhancing the antigen-pre-
senting function of DC. 
  Although it is believed that nucleosomes constitute one 
of the primary autoantigens in SLE, previous attempts to im-
munize nonautoimmune mice with nucleosomes purifi  ed 
from viable cells failed to trigger relevant autoantibody pro-
duction (  30  ). In agreement with these previous studies, we 
also did not observe a signifi  cant induction of anti-dsDNA anti-
bodies after immunization with nucleosomes from viable cells. 
Importantly, immunization with HMGB1  –  nucleosome com-
plexes from apoptotic cells, which activate macrophages and 
induce DC maturation in vitro, translated into signifi  cantly 
increased anti-dsDNA antibody generation in nonautoim-
mune mice. Mevorach et al. (  67  ) immunized nonautoimmune 
mice with whole apoptotic cells but could not detect anti-
bodies against dsDNA, only antibodies against ssDNA. The 
failure of whole apoptotic cells to induce disease relevant anti-
dsDNA antibodies in nonautoimmune mice may be caused 
by the rapid clearance of apoptotic cells and their antiinfl  am-
matory and immunosuppressive properties (  68  ). 
  In summary, HMGB1-containing apoptotic cell  –  derived 
nucleosomes may critically contribute to break peripheral tol-
erance against nuclear antigens in SLE via their proinfl  amma-
tory actions on various cell types, especially macrophages and 
DC. Moreover, our fi  ndings implicate that antagonizing of 
HMGB1 might represent a novel treatment strategy for SLE. 
  MATERIALS AND METHODS 
  Serum samples.     For serum preparation, venous blood was collected from 
healthy donors and patients with SLE or other diseases into tubes without 
anticoagulants (Monovette) and centrifuged at 2,000   g   for 30 min at 4  °  C. 
Serum was collected and stored at     20  °  C. The study was approved by the 
ethics committee of the Medical Faculty at the University of Erlangen-
Nuremberg (Ethikkommission der Medizinischen Fakult  ä  t der Friedrich-
Alexander-Universit  ä  t Erlangen-N  ü  rnberg) and informed consent of blood 
donors was obtained. 
  Cell culture.     Jurkat (TIB-152) cells were cultured as previously described 
(  22  ).   Hmgb1    +/+   and   Hmgb1        /      MEF were obtained from sib embryos from 
crosses of   Hmgb1   heterozygotes on a pure BALB/c genetic background (  >  10 
backcrosses) and grown according to the 3T3 protocol, which prescribes 
splitting the growing cells 1:3 every 3 d for 3 mo. Fibroblasts obtained at the 
end of this procedure can be maintained indefi  nitely as monolayer cultures 
in complete DMEM. Fibroblast lines derived in this way express a low level 
of HMGB2 protein and no detectable HMGB3 mRNA in addition to being 
KO for HMGB1. We then refer to them as HMGB  low  , and the WT coun-
terparts are referred to as HMGB  +  . Human monocyte-derived macrophages 
were diff  erentiated as described previously (  69  ). Human monocyte-derived 
DC were generated as previously described (  13  ). Thioglycollate-elicited mouse 
peritoneal macrophages were obtained according Michl et al. (  70  ). T lym-
phocytes were isolated by negative immunomagnetic selection from PBMC 
of healthy donors using the Pan T Cell Isolation kit II (Miltenyi Biotec). 
  Animals.     Animal experiments were approved by the government of 
Mittelfranken (Regierung von Mittelfranken). Mice were housed in the animal 
facility of the University of Erlangen-Nuremberg. BALB/c and C57BL/6 
mice were purchased from Charles River Laboratories. RAGE      /      mice 3016 HMGB1  –  NUCLEOSOME COMPLEXES IN SLE   | Urbonaviciute et al. 
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  Measurement of cytokines.     Concentrations of the cytokines TNF-    , IL-10, 
and IL-1     in cell culture supernatants of human monocyte-derived macro-
phages were determined using pairs of matched monoclonal antibodies (BD). 
IL-6, IL-8, IL-18, IFN-    , and IFN-     were measured by FlowCytomix bead-
based assay (Bender MedSystems) according to the manufacturer  ’ s instructions. 
  Flow cytometric analyses.     Monocyte-derived DC (5   ×   10  5  ) were incu-
bated at 4  °  C for 30 min with fl  uorochrome-conjugated monoclonal anti-
bodies against CD83-PE (Beckman Coulter), CD86-biotin (BD), HLA-DR 
(Beckman Coulter), or appropriate isotype controls in PBS containing 2% 
FBS. Labeled cells were washed twice and analyzed using a FACSCalibur 
(BD). Data were analyzed using the Cell Quest software (BD). 
  Mixed leukocyte reaction.     Day-7 immature monocyte-derived DC were 
either left untreated or incubated with 20   μ  g/ml of nucleosomes from viable 
or apoptotic Jurkat cells in RPMI 1640 medium supplemented with 10% 
autologous human serum. After incubation for 48 h, 1   ×   10  3   irradiated (30 
Gy) DC were plated together with 1   ×   10  5   allogeneic T cells in a fi  nal vol-
ume of 200   μ  l in round-bottomed 96-well plates. Cells were cocultured for 
5 d and pulsed with 1   μ  Ci   3  H thymidine per well (Amersham Biosciences) 
during the fi  nal 16 h of culture. Incorporation of   3  H thymidine was mea-
sured on a 1205 Wallac Beta counter (GE Healthcare). Thymidine incorpo-
rations are reported as mean cpm of triplicates   ±   SD. 
  Immunization.     6-wk-old female BALB/c mice were i.v. injected three 
times at an interval of 3 wk with 50   μ  g of nucleosomes purifi  ed either from 
apoptotic or viable Jurkat cells. The control group received PBS. Serum 
samples were taken before immunization and 3 wk after each immunization. 
  8-wk-old TLR2      /      or TLR2/4      /      mice (  41  ) were i.v. injected with 
75   μ  g of nucleosomes purifi  ed from apoptotic Jurkat cells. C57BL/6 mice 
served as controls. All groups of mice received three injections of apoptotic 
nucleosomes at an interval of 2 wk. 
  Determination of autoantibodies.     The concentrations of IgG antibodies 
to dsDNA, ssDNA, and histones in the sera were determined by ELISA as 
previously described (  73, 74  ). 
  Statistical analyses.     Statistical analyses were performed using either the 
two-tailed Student  ’  s   t   test for heteroscedastic samples or Mann-Whitney   U   
test for unpaired samples as appropriate and indicated in the fi  gure legends. 
  Online supplemental material.     Fig. S1 shows similar cytokine secre-
tion by human macrophages stimulated with nucleosomes biochemically 
purifi  ed from early versus late apoptotic Jurkat cells using sucrose gradient 
ultracentrifugation as described in Materials and methods. Fig. S2 shows 
that nucleosomes, which were spontaneously released from late apop-
totic/secondary necrotic cells, contain HMGB1 and induce TNF-     and 
IL-10 release from human macrophages. Fig. S3 demonstrates that nu-
cleosomes isolated from either viable or apoptotic cells do not stimulate 
IFN-     release from human pDC. However, nucleosomes together with 
anti-dsDNA antibodies containing serum induced a strong IFN-     release 
that was comparable to CpG oligonucleotides. Fig. S4 shows the induc-
tion of anti-Sm antibodies in BALB/c mice that had been immunized 
three times with apoptotic nucleosomes but not in those mice that had 
been immunized with viable nucleosomes. Fig. S5 displays a proposed 
model of the role of HMGB1  –  nucleosome complexes in immunopatho-
genesis of SLE. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20081165/DC1. 
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